Clinical Guideline Alerts - September 2023 Banner
FDA Drug Approvals - September 2023 Banner
  • Aphexda (BioLineRx)
    • In combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.
  • Temodar (Merck) Expanded Indication
    • Adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma; treatment of adults with refractory anaplastic astrocytoma.
  • Ojjaara (GlaxoSmithKline) 
    • Treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythaemia), in adults with anaemia.
  • Talicia (RedHill Biopharma) New Formulation
    • New simplified dosing regimen – three times daily (TID) regimen for H. pylori eradication.
  • Jardiance (Boehringer Ingelheim / Eli Lilly) New Indication
    • To reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death and hospitalization in adults with chronic kidney disease (CKD) at risk of progression.
  • Exxua (Fabre-Kramer Pharmaceutical) 
    • To treat major depressive disorder.
  • Likmez (Saptalis Pharmaceuticals / Appili Therapeutics) 
    • Treatment of Parasitic and Anaerobic Bacterial Infections.
  • Ryzumvi (Viatris / Ocuphire Pharma)
    • Treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents.
  • Bosulif (Pfizer) 
    • For pediatric patients aged 1 year or older with chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) that is either newly diagnosed or resistant/intolerant to prior therapy.
  • Entyvio (Takeda) New Formulation
    • Subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) following induction therapy with intravenous administration of vedolizumab.
  • Pombiliti + Opfolda (Amicus Therapeutics) 
    • To treat late-onset Pompe disease.

Copyright © 2023 Guideline Central, All rights reserved.